1. Articles in category: Drug

    1-24 of 322 1 2 3 4 ... 12 13 14 »
    1. PRecISion Medicine for Children With Cancer

      PRecISion Medicine for Children With Cancer

      Conditions :   Childhood Cancer;   Childhood Solid Tumor;   Childhood Brain Tumor;   Childhood Leukemia;   Refractory Cancer;   Relapsed Cancer Intervention :   Diagnostic Test: Molecular profiling and drug testing Sponsors :   Sydney Children's Hospitals Network;   Children's Cancer Institute Australia;   Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG);   Garvan Institute of Medical Research;   German Cancer Research Center (DKFZ) Recruiting

      Read Full Article
    2. Emerging and investigational therapies for neuroblastoma.

      Emerging and investigational therapies for neuroblastoma.

      Expert Opin Orphan Drugs. 2017;5(4):355-368

      Authors: Applebaum MA, Desai AV, Glade Bender JL, Cohn SL

      Abstract INTRODUCTION: Treatment for children with clinically aggressive, high-risk neuroblastoma remains challenging. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities.

      Read Full Article
      Mentions: Treatment
    3. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.

      Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.

      Carcinogenesis. 2017 Aug 29;:

      Authors: Russo R, Cimmino F, Pezone L, Manna F, Avitabile M, Langella C, Koster J, Casale F, Raia M, Viola G, Fischer M, Iolascon A, Capasso M

      Read Full Article
    4. A Cell-Cycle "Safe Space" for Surviving Chemotherapy.

      A Cell-Cycle "Safe Space" for Surviving Chemotherapy.

      Cell Syst. 2017 Sep 27;5(3):161-162

      Authors: Arora M, Spencer SL

      Abstract Live-cell imaging demonstrates that a subset of neuroblastoma cells evades chemotherapy-induced death if they are in early G1 phase of the cell cycle at the time of drug treatment and have sufficiently high levels of MYCN.

      PMID: 28957649 [PubMed - in process]

      Read Full Article
    5. GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      Cancer Discov. 2017 Sep 22;:

      Authors:

      Abstract A GPC2-targeting antibody-drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

      PMID: 28939655 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Antibody
    6. Patient-derived xenografts as preclinical neuroblastoma models.

      Patient-derived xenografts as preclinical neuroblastoma models.

      Cell Tissue Res. 2017 Sep 19;:

      Authors: Braekeveldt N, Bexell D

      Abstract The prognosis for children with high-risk neuroblastoma is often poor and survivors can suffer from severe side effects. Predictive preclinical models and novel therapeutic strategies for high-risk disease are therefore a clinical imperative.

      Read Full Article
      Mentions: Side Effects
    7. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Expert Opin Investig Drugs. 2017 Sep 14;:

      Authors: Amoroso L, Haupt R, Garaventa A, Ponzoni M

      Abstract INTRODUCTION: Neuroblastoma (NB) is an embryonal tumor originating from undifferentiated neural crest cell, highly heterogeneous ranging from spontaneous regression to progression despite multimodal treatments.

      Read Full Article
      Mentions: Treatment
    8. Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Cancer Cell. 2017 Sep 11;32(3):271-273

      Authors: Malone CF, Stegmaier K

      Abstract In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.

      Read Full Article
      Mentions: Antibody
    9. RACE for Children Act Becomes Law!

      RACE for Children Act Becomes Law!

      WASHINGTON, Aug. 19, 2017 /PRNewswire/ -- Yesterday, the RACE for Children Act became law, ensuring that novel and exciting new cancer drugs will now be developed not only for adults, but also for children with cancer. Nancy Goodman, CEO of Kids v Cancer stated, "One of the greatest...

      Read Full Article
    10. Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.

      Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.

      J Exp Clin Cancer Res. 2017 Aug 16;36(1):111

      Authors: Wang Y, Chen K, Cai Y, Cai Y, Yuan X, Wang L, Wu Z, Wu Y

      Abstract BACKGROUND: Chemotherapy is one of major therapeutic regimens for neuroblastoma (NB) in children. However, recurrence and metastasis associated with poor prognosis caused by acquired multidrug resistance remains a challenge.

      Read Full Article
    11. A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

      Conditions :   Relapsed or Refractory Malignancies;   Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL);   Relapsed or Refractory Acute Myeloid Leukemia (AML);   Relapsed or Refractory Non-Hodgkin Lymphoma (NHL);   Relapsed or Refractory Neuroblastoma;   Relapsed or Refractory Tumors That Expresses B Cell Lymphoma 2 (BCL-2) Interventions :   Drug: venetoclax;   Drug: chemotherapy Sponsors :   AbbVie;   Genentech/Roche Not yet recruiting - verified July 2017

      Read Full Article
      Mentions: Refractory
    12. New strategy against childhood cancer

      New strategy against childhood cancer

      Neuroblastoma is a cancer in children that originates in the sympathetic nervous system and has a high mortality. Current treatment includes chemotherapy and radiotherapy with their potentially severe side effects; there is therefore an urgent need for a new improved drug. One potential treatment strategy is to use a drug to target deviant molecular signalling caused by changes in genes.

      Read Full Article
    13. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.

      Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.

      Oncotarget. 2017 Jul 04;:

      Authors: Van Goethem A, Yigit N, Moreno-Smith M, Vasudevan SA, Barbieri E, Speleman F, Shohet J, Vandesompele J, Van Maerken T

      Abstract Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy.

      Read Full Article
    14. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Biochem Biophys Res Commun. 2017 Jul 12;:

      Authors: Li Y, Zhuo B, Yin Y, Han T, Li S, Li Z, Wang J

      Abstract Chemotherapy is one of the few effective choices for patients with neuroblastoma. However, the development of muti-drug resistance (MDR) to chemotherapy is a major obstacle to the effective treatment of advanced or recurrent neuroblastoma.

      Read Full Article
    15. Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to entrectinib for “treatment of NTRK fusion-positive solid tumors.” NTRK fusions are molecular alterations that occur in a broad variety of adult and pediatric solid tumor types. Entrectinib is the company’s investigational, orally available, CNS-active tyrosine kinase inh

      Read Full Article
      Mentions: Treatment ALK
    16. Optimization of liposomal topotecan for use in treating neuroblastoma.

      Optimization of liposomal topotecan for use in treating neuroblastoma.

      Cancer Med. 2017 May 23;:

      Authors: Chernov L, Deyell RJ, Anantha M, Dos Santos N, Gilabert-Oriol R, Bally MB

      Abstract The purpose of this work was to develop an optimized liposomal formulation of topotecan for use in the treatment of patients with neuroblastoma.

      Read Full Article
      Mentions: Treatment
    17. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      Drug Deliv Transl Res. 2017 Apr 21;:

      Authors: Gilabert-Oriol R, Chernov L, Anantha M, Dragowska WH, Bally MB

      Abstract Topotecan is a drug that is under investigation for the treatment of neuroblastoma and has been encapsulated into liposomes to improve its therapeutic efficacy.

      Read Full Article
      Mentions: Treatment
    18. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Exp Biol Med (Maywood). 2017 Jan 01;:1535370217706952

      Authors: Cooper JP, Reynolds CP, Cho H, Kang MH

      Abstract Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells.

      Read Full Article
    19. Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA.

      Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA.

      Pediatr Res. 2017 Apr 18;:

      Authors: Duong C, Yoshida S, Chen C, Barisone G, Diaz E, Li Y, Beckett L, Chung J, Antony R, Nolta J, Nitin N, Satake N

      Abstract BACKGROUND: Neuroblastoma is the second most common extracranial cancer in children.

      Read Full Article
    1-24 of 322 1 2 3 4 ... 12 13 14 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. General Informations in the News

    1. (1 articles) Treatment